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Background: For many healthcare decisions, multiple alternatives are available with different combinations of
advantages and disadvantages across several important dimensions. The complexity of current healthcare decisions
thus presents a significant barrier to informed decision making, a key element of patient-centered care.
Interactive decision dashboards were developed to facilitate decision making in Management, a field marked by
similarly complicated choices. These dashboards utilize data visualization techniques to reduce the cognitive effort
needed to evaluate decision alternatives and a non-linear flow of information that enables users to review
information in a self-directed fashion. Theoretically, both of these features should facilitate informed decision
making by increasing user engagement with and understanding of the decision at hand. We sought to determine
if the interactive decision dashboard format can be successfully adapted to create a clinically realistic prototype
patient decision aid suitable for further evaluation and refinement.
Methods: We created a computerized, interactive clinical decision dashboard and performed a pilot test of its
clinical feasibility and acceptability using a multi-method analysis. The dashboard summarized information about
the effectiveness, risks of side effects and drug-drug interactions, out-of-pocket costs, and ease of use of nine
analgesic treatment options for knee osteoarthritis. Outcome evaluations included observations of how study
participants utilized the dashboard, questionnaires to assess usability, acceptability, and decisional conflict, and an
open-ended qualitative analysis.
Results: The study sample consisted of 25 volunteers - 7 men and 18 women - with an average age of 51 years.
The mean time spent interacting with the dashboard was 4.6 minutes. Mean evaluation scores on scales ranging
from 1 (low) to 7 (high) were: mechanical ease of use 6.1, cognitive ease of use 6.2, emotional difficulty 2.7,
decision-aiding effectiveness 5.9, clarification of values 6.5, reduction in decisional uncertainty 6.1, and provision of
decision-related information 6.0. Qualitative findings were similarly positive.
Conclusions: Interactive decision dashboards can be adapted for clinical use and have the potential to foster
informed decision making. Additional research is warranted to more rigorously test the effectiveness and efficiency
of patient decision dashboards for supporting informed decision making and other aspects of patient-centered
care, including shared decision making.Background
An important component of quality healthcare is patient-
centeredness, defined by the Institute of Medicine as
“… care that is respectful of and responsive to individual
patient preferences, needs, and values and ensuring that
patient values guide all clinical decisions” [1]. Despite its* Correspondence: james_dolan@urmc.rochester.edu
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reproduction in any medium, provided the orimportance, providing patient-centered care is a complex
task that involves integrating clinical evidence, biomedical
data, and other technical information with patients’ per-
sonal preferences, circumstances, and values.
Patient decision aids are intended to facilitate this
process. They are “evidence-based tools designed to pre-
pare clients to participate in making specific and deliber-
ated choices among healthcare options” [2]. Patient
decision aids have been shown to increase patients’ know-
ledge, reduce decisional conflict, and foster patient in-
volvement in decisions about their care [2-4]. However,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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their use, the most effective way(s) to design and build
patient decision aids is unknown, their effect on out-
comes is uncertain, and we do not know how to most
effectively integrate patient decision aids into busy prac-
tice settings [5-7].
A key challenge for patient decision aids is to help pa-
tients make sense of new, unfamiliar information about
alternative management strategies so that they can make
informed judgments about which ones they prefer [8].
Increasingly, healthcare decisions involve multiple alter-
natives with varying combinations of advantages and dis-
advantages. The presentation of unfamiliar information
can lead to an incomplete understanding of the decision
task and the consideration of multiple alternatives across
various attributes is a substantial cognitive load for deci-
sion makers. Circumstances like these can cause people
to make sub-optimal decisions or even avoid making a
choice [9,10].
The need to quickly and effectively integrate large
amounts of information across several dimensions is not
unique to health care decisions. Busy decision makers in
many different contexts face similar challenges. Ad-
vances in cognitive science and computer technology
have led to increasing interest in the use of interactive
visual information displays to support decision making
in these circumstances [11,12]. One of the first products
of these activities is the computer-based, interactive de-
cision dashboard. Interactive decision dashboards are
being increasingly used in business settings [13]. In
healthcare, dashboards have been used to advance qual-
ity improvement [14-17], medication safety [18], inten-
sive care unit patient management [19], implementation
and monitoring of mental health care guidelines [20],
and patient wellness [21].
A decision dashboard is “… a visual display of the most
important information needed to achieve one or more ob-
jectives; consolidated and arranged on a single screen so
the information can be monitored at a glance” [13]. The
key components of decision dashboards include: a visual
summary of decision-related information displayed in a
single view, extensive use of graphical information dis-
plays, and features that allow users to easily interact with
and explore the information being presented. These com-
ponents allow dashboards to quickly communicate infor-
mation about the pros and cons of decision alternatives by
reducing the cognitive effort required by structuring the
decision, highlighting factors that merit consideration,
making the information more evaluable by actively en-
gaging well-developed human visual capabilities to help
people process and understand information, and providing
information in a non-linear format to facilitate its incorp-
oration in decision making deliberations [12,13,22-29].
Additionally, because dashboards allow users to controlthe extent and content of information displayed, they pro-
vide a means for users to self-regulate information expos-
ure and avoid overload in the face of large amounts of
information [22]. Theoretically, clinical decision dash-
boards that are properly formatted to take maximum
advantage of inherent human visual and cognitive capabil-
ities could provide a way to promote informed decision
making effectively and efficiently [11].
The similarity between the purpose of a patient deci-
sion aid and the functionality of interactive decision
dashboards suggests the dashboard format could be a
useful way to create decision aids capable of facilitating
informed decision making about complex, unfamiliar
healthcare issues and promoting patient-centered care in
busy clinical settings. To our knowledge, however, the
use of interactive dashboards to support clinical decision
making has not been explored. The goal of this study
was determine if the interactive decision dashboard for-
mat can be successfully adapted to create a clinically
realistic and feasible patient decision aid prototype suit-
able for further refinement and evaluation.
Methods
Patient decision aids are complex health interventions.
The objective of this initial study was to complete phases
one and two - theoretical development and development
of the intervention - of the five phase methodology for
studying the effects of complex health interventions pro-
posed by the British Medical Research Council [30,31].
Development of the prototype clinical decision
dashboard
We based our clinical dashboard prototype on a patient
decision aid regarding selection of non-opioid pain
medication for treatment of osteoarthritis pain produced
by the Agency for HealthCare Research and Quality
(AHRQ) [32,33]. We chose this example because deci-
sions regarding medication use, particularly for patients
with chronic illnesses, are among the most common
clinical decisions made and frequently depend on indi-
vidual patient preferences and circumstances.
The AHRQ brochure contains information about the
beneficial effects of non-opioid analgesics on joint pain
and swelling, risks of stomach bleeding, liver and kidney
problems, and medication costs. Additional considerations
regarding choice of treatment noted in the literature in-
clude risk of common side effects such as nausea and
heartburn, likelihood of benefit in terms of decreased pain
and improved function, possible interactions with co-
existing conditions or other medications, speed of onset of
pain relief, and method of administration [34,35]. A pa-
tient focus group conducted at the beginning of the study
identified several additional factors affecting choice of
osteoarthritis pain medication, including specific concerns
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tion administration issues such as the number of daily
doses and when pain medications should be taken rela-
tive to food and other drugs. Based on this information,
we included the following medication characteristics in
the prototype decision dashboard: effectiveness in re-
lieving pain, risk of side effects, possibility of drug-drug
interactions, out-of-pocket cost, and how the drug is
administered.
To allow for comparisons between the dashboard
prototype and the AHRQ brochure we included the
same treatment options in the dashboard. Data needed
to describe the drug choices relative to each decision cri-
terion were obtained as follows:
 We used the overall effect sizes from a meta-analysis
published shortly before we created the dashboard
prototype to summarize effectiveness [36].
 We estimated side effect risks using information
obtained from the comparative effectiveness review
that served as the basis for the AHRQ decision aid, a
meta-analysis of osteoarthritis pain medications, and
the MEDEX® drug database [33,36,37]. We defined
low risk as no serious side effects and three or fewer
common side effects, moderate risk as one to three
serious side effects or four to ten common side
effects, and high risk as either four or more serious
side effects or more than ten common side effects.
 We obtained information about possible drug-drug
interactions from the Lexi-Comp Online™
Interaction Lookup database [38]. We defined low
risk as no known interactions, moderate risk as
interactions possible but not thought to be clinically
important, and high risk as some interactions
possible that could affect patient care.
 Cost estimates, recommended dosing schedules, and
routes of administration were obtained from the
Tarascon Pharmacopoeia, Mobile version [39]. WeTable 1 Drug-related information included in the dashboard
Drug (Dashboard abbreviation) Pain relief * Risk of side effects
Acetaminophen (a) 0.21 Low
Topical NSAID (b) 0.41 Low
Capsaicin (c) 0.30 Low
NSAID + misoprostol (d) 0.32 High
NSAID + PPI (e) 0.32 Moderate
NSAIDs (f) 0.32 Moderate
Celecoxib (g) 0.44 Moderate
Chondroitin sulfate (h) 0.30 Low
Glucosamine sulfate (i) 0.45 Low
* - Pain relief summarized using reported effect size.
Abbreviations: NSAID = non-steroidal anti-inflammatory drug; PPI = proton pump indefined low cost as patient out-of-pocket expenses
of $5 to $10 per month, moderate cost as $11 to $25
per month, high cost as $26 to $50 per month, and
very high cost as monthly out-of-pocket expenses of
more than $50.
Table 1 summarizes the treatment-related information
included in the dashboard prototype. This information
was current at the time of the study (2008–09). To
avoid respondent bias due to past treatment experiences
or name recognition, we identified the options on the
dashboard using arbitrary letters rather than the actual
drug names. Note that the data indicate that two op-
tions, - non-steroidal anti-inflammatory drugs plus mi-
soprostol and non-steroidal anti-inflammatory drugs
and proton pump inhibitors - can be considered inferior
choices because other treatment options are available
that are better with respect to every medication charac-
teristic being considered.
The main screen of the resulting dashboard prototype
is shown in Figure 1. It consists of five windows that
summarize the relative performance of the treatment al-
ternatives with regard to each of the included drug in-
formation categories: effectiveness in relieving pain, risk
of side effects, possibility of drug-drug interactions, out-
of-pocket cost, and how the drug is administered. But-
tons for obtaining additional category-specific information
are included within the window for every category
except administration. There are also buttons at the
bottom of the display that can be used to prioritize the
importance of each drug information category in mak-
ing a treatment choice and to determine which drugs
are included in the display.
We designed the dashboard prototype following
guidelines proposed by Few [13] and programmed it
using Microsoft Excel and Crystal Xcelsius, a program
designed to create interactive decision dashboards from
Excel files [40,41].Risk of drug-drug interactions Cost Administration
Moderate Low 1 tablet every 6 hours
Low High Cream twice a day
Low Moderate Cream twice a day
High Moderate 2 tablets twice a day
High Very High 2 tablets twice a day
High Low 1 tablet twice a day
High High 1 tablet twice a day
Low Moderate 1 tablet twice a day
Moderate Moderate 1 tablet twice a day
hibitor.
Figure 1 The decision dashboard.
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We tested the usability and effectiveness of the clinical
dashboard prototype by recruiting study volunteers from
nursing and secretarial staff working at Unity Faculty
Partners (a general internal medicine resident/faculty
teaching practice affiliated with Unity Health System in
Rochester NY), patients from the same practice, Unity
Hospital Department of Medicine support staff, and vol-
unteers responding to a notice about the study posted
on the University of Rochester Medical Center clinical
trials website. The study was conducted over a three
month period between February 12 and May 5, 2009.
After a brief introduction, study participants were
asked to: a) imagine they had developed symptomatic
osteoarthritis in their right knee that was interfering
with their usual activities, b) that their physician had
asked them to use the dashboard to review possible ini-
tial treatment options in preparation for an upcoming
appointment and choose a preferred medication, and
c) after a brief instructional demonstration, to use it to
help them identify a preferred treatment option. All par-
ticipants individually reviewed the dashboard running on
a personal computer equipped with a touch screen moni-
tor in a private setting.
If a participant actually had arthritis, we asked them to
make their treatment choice as if they had no arthritic
problems other than the knee pain that was described.
Otherwise, we instructed study participants to select apreferred treatment option based on their actual per-
sonal circumstances and preferences.
Evaluation
We evaluated the potential usefulness of the clinical
dashboard format for creating clinically realistic and
feasible patient decision aids using a multi-method pro-
cedure that included observations of how the study par-
ticipants used the dashboard, measures designed to
assess ease of use, acceptability, and decisional conflict,
and an open-ended qualitative analysis.
The observational data included the time the partici-
pants spent using the dashboard before choosing a pre-
ferred drug, which drug they chose, and whether they
used three optional features included in the dashboard:
the touch screen option, the priority boxes assigned to
each consideration, and the opportunity to remove infor-
mation about specific drugs from the dashboard display.
The remainder of the evaluation was conducted after
the participants had finished using the dashboard and
selected their preferred drug. The first part consisted of
a 21 item questionnaire designed to measure the dash-
board’s ease of use and acceptability derived from two
validated instruments to measure users’ evaluations of
computer-based tools: the Unified Theory of Acceptance
and Use of Technology (UTAUT) [42] and the WebQual
instrument [43]. We used items from both scales chosen
to eliminate redundancy and adapted them to fit a
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cluded four component sub-scales: mechanical ease of use
(4 items), cognitive ease of use (7 items), emotional diffi-
culty (3 items), and decision-aiding effectiveness (7 items).
Possible responses to all items consisted of a 7-point scale
ranging from strongly disagree to strongly agree. Sub-
scale scores were calculated using the mean item re-
sponse. The resulting scale is shown in Table 2.
We assessed the effect of the dashboard on partici-
pants’ decision making processes using the informed,
values clarity, and uncertainty sub-scales from the deci-
sional conflict scale modified to use a 7 rather than a 5
point scale to be consistent with the other assessment
questions [44].Table 2 Quantitative outcome measures *
Scale component Items
Ease of use, mechanical a. I found the program ea
b. It was easy to find info
c. The design of the prog
d. I think I could learn to
Ease of use, cognitive a. I found the program cl
b. The program provides
c. The program provides
d. The program provides
e. The program provides
f. The program provides i
g. The program provides
Ease of use, emotional a. I felt nervous using the
b. I would not wish to us
would make mistakes.
c. The program was intim
Decision-aiding effectiveness a. I would find this progr
b. Using this program wo
c. Using this program wo
effectively.
d. If I could, I would use
e. I think the program wo
treatment.
f. I feel confident that the
g. The program would he
Decisional conflict scale, informed sub-scale a. I know what options a
b. I know the benefits of
c. I know the risks & side
Decisional conflict scale, values clarification
sub-scale
a. I am clear about which
b. I am clear about which
c. I am clear about which
Decisional conflict scale, uncertainty sub-
scale
a. I am clear about the be
b. I feel sure about what
c. The decision is easy for
* Possible responses to all items consisted of a 7-point scale ranging from strongly
item response.The qualitative analysis consisted of a series of open-
ended questions exploring aspects of the participants’
experiences using the dashboard for the task of picking
their preferred arthritis pain medication and to compare
the dashboard with the conventionally formatted AHRQ
booklet. The questions included in this phase of the ana-
lysis are shown in Additional files 1 and 2.
We used participant self-reports to determine age, ra-
cial background, and highest educational level attained.
We measured health-related literacy and numeracy
using the Rapid Estimate of Adult Literacy in Medicine
(REALM), the subjective numeracy scale, and the
Newest Vital Sign. The REALM is a test of word recog-
nition that correlates well with other commonly usedsy to use
rmation and move through the program.
ram was appropriate.
use the program on my own.




easy to understand information.
nformation at the right level of detail.
information in an appropriate format.
program.
e the program to help with my medical care because I am afraid I
idating to me.
am useful in treating my arthritis pain.
uld help me learn about my treatment options more quickly.
uld increase my chances of controlling my arthritis pain safely and
this program.
uld make it easier for me to talk to my doctor about my arthritis pain
program would help me treat my arthritis pain better.
lp me get the arthritis treatment that is best for me.
re available to me for treating my arthritis pain.
each option.
effects of each option.
benefits matter most to me.
risks and side effects matter most to me.
benefits, risks, and side effects matter most to me.
st choice for me.
to choose.
me to make.
disagree to strongly agree. Sub-scale scores were calculated using the mean
Table 3 The study sample
Variable Number (percent)
Gender Male: 7 (28%)
Female: 18 (72%)




Highest Education level High School or less: 3 (12%)
Some college, no degree: 3 (12%)
Associate’s degree: 11 (44%)
Bachelor’s degree: 4 (16%)
Post-graduate training: 4 (16%)
Recruitment source Office staff: 7 (28%)
Website volunteer: 8 (32%)
Practice volunteer: 6 (24%)
Department staff volunteer: 4 (16%)
Newest Vital Sign Health
Literacy category
Adequate literacy: 18 (72%)
Possible limited literacy: 5 (20%)
High likelihood limited literacy: 2 (8%)
REALM grade level High School: 21 (84%)
7th – 8th grade: 3 (12%)
4th to 6th grade: 1 (4%)
Mean (sd, range)
Age, years 51.4, (13.8, 22 to 71)
Subjective numeracy scale 4 (0.75, 2.25 to 5.38)
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level equivalents [45]. The subjective numeracy scale
consists of eight items and does not require any calcu-
lations. Scores range from 1 to 6 with higher scores in-
dicating greater numeracy skills [46]. The Newest Vital
Sign involves reading and interpreting information
provided about the nutritional information of a con-
tainer of ice cream. It has been shown to be a quick
and reliable assessment of health literacy in primary
care settings [47].
The study was approved by the institutional review
boards of the University of Rochester and Unity Health
System.
Data analysis
We summarized quantitative data using standard de-
scriptive statistical methods and evaluated the qualitative
data using a thematic approach. The reliability of the
outcome questionnaires was assessed using Cronbach’s




The characteristics of the study sample are summarized
in Table 3. The majority were white women with at least
an Associate’s degree and good to excellent literacy and
numeracy skills. They were recruited in almost equal
proportions from office and departmental staff, patient
volunteers, and clinical trial website respondents.
Dashboard use
The average time participants spent interacting with the
dashboard was 4.6 minutes (range 0.4 to 11.7). The most
commonly used extra feature of the dashboard was the
option to delete the display of information about indi-
vidual treatment options which was utilized by 14 (56%)
participants. The other extra features were used less
often. Five (25%) participants used the importance boxes
and two (10%) of twenty who had the opportunity to use
a touchscreen used it instead of a mouse to interact with
the dashboard. (A working touchscreen was not available
for the other five participants).
Decision outcomes
The most commonly preferred drug was chondroitin
sulfate, selected by 11 (48%) participants. The drug pref-
erences of the other 14 participants were divided across
six of the remaining eight options. Overall, seven (78%)
of the nine treatment alternatives included in the dash-
board were preferred by at least one participant. Only
one patient selected an apparently inferior treatment
choice (non-steroidal anti-inflammatory drugs and pro-
ton pump inhibitor, NSAIDS + PPI).Quantitative decision making process evaluations
The results of the quantitative evaluation are summa-
rized in Figure 2. Detailed results are included in a Add-
itional files 1 and 2. The response rates were 100% for
17 (57%) of the 30 individual questions, 96% for 7 ques-
tions, and 92% for the other 6. The responses are con-
sistently positive for questions concerning mechanical
and cognitive ease of use, decision aiding effectiveness,
and effectiveness in reducing decisional conflict by pro-
viding needed information, clarifying values, and easing
uncertainty. There was no evidence of adverse emotional
consequences. The Cronbach’s alpha coefficient for the
21-item adapted ease of use and acceptability scale was
0.90; for the three combined decisional conflict subscales
it was 0.89.
Qualitative decision making process evaluation
All participants answered the open-ended questions. By
and large, they reported finding the computerized dash-
board easy to use and helpful in evaluating medication
choices for osteoarthritis pain and, potentially, for treat-
ment decision-making more generally. Participants appre-
ciated the simplicity of the tool, the graphic display of
information, and the ability to compare specific treatment
Figure 2 Results of the quantitative decision making process
assessment. Dotplots showing the scores representing the mean
quantitative assessment responses for the sub-scales used for the
quantitative decision making process assessment. Abbreviations
Mech = mechanical ease of use scale (4 items); Cog = cognitive ease
of use scale (7 items); Emo = emotional ease of use scale (3 items);
DAE = decision aiding effectiveness scale (7 items); DCSI = decisional
conflict scale, informed sub-scale; DCSV = decisional conflict
scale, values sub-scale; DCSU = decisional conflict scale,
uncertainty sub-scale.
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the ability to “turn off” information they deemed person-
ally irrelevant or unimportant). Some were surprised by
the ways the dashboard revealed and helped prioritize
their values regarding specific kinds of pain medication,
their administration, and their cost.
Some respondents desired more evidence-based infor-
mation about specific medications, including how long
they had been in use, potential serious or long-term side
effects, and how the drugs actually work in the body (in-
cluding how quickly they take effect). Additionally, some
questioned the source of the information (about the dif-
ferent medications) displayed on the dashboard and its
accuracy.
Uniformly, respondents expressed that they would like
ultimate choices about their pain medication to be made
in collaboration with a doctor. In other words, they
would not want to rely on their own judgment, even if
assisted by a brochure or a computerized aid, to come to
treatment decisions. Rather, they saw the utility of the
computerized aid as educational and preparatory for
their discussions with a doctor which would lead to final
decisions about treatment choices through a shared de-
cision making process.
When asked to choose between using the dashboard
and the AHRQ brochure as a decision aid, 12 (48%) par-
ticipants preferred the dashboard, 5 (20%) preferred the
AHRQ brochure, and 8 (32%) preferred a combined
approach.Discussion
These results suggest that the interactive decision dash-
board format can be adapted to serve as a patient deci-
sion aid. The majority of our study participants were
able to use the clinical dashboard prototype to work
through a complicated decision problem in a remarkably
efficient manner with excellent results in terms of ease-
of-use, information provided, clarification of decision-
related values, resolution of uncertainty about the treat-
ment choice, and overall usefulness. As demonstrated by
the positive responses to the usability and decisional
conflict scales, we did not find evidence that the dash-
board induced information overload. In fact, partici-
pants’ frequent use of the dashboard to eliminate less
desirable options to focus attention on more promising
alternatives suggests that the dashboard format provided
a useful way for them to work through a large amount
of information without being overwhelmed by it. There
was no evidence of adverse emotional effects. A number
of participants specifically commented that they found
the dashboard display especially useful in identifying the
key trade-offs involved in the decision, and 80% felt that
a decision dashboard would be a valuable educational
tool, either alone or in conjunction with complementary
written material, to prepare them to participate in a
shared decision making process with their health care
provider.
These results are consistent with those of previous
studies that have examined important features of the
interactive dashboard format in isolation. Comparative
studies have shown graphic formats more effective than
numeric information for comparing the likelihoods
of different outcomes, minimizing decision biases due
to vivid anecdotal information, and promoting under-
standing of information by patients, including those
over 75 years of age [49-53]. These studies all provide
evidence supporting the theoretical advantages of visual
information formats for supporting human decision
making processes. There is also evidence that data
about alternatives presented in a single side by side view
promotes more effective comparisons and differenti-
ation among decision alternatives [8,54-56]. Finally,
positive results have been found using patient decision
boards - which are essentially static, non-interactive
dashboards - to support clinical decision making in On-
cology [57,58].
This study has several limitations. Because the deci-
sion task involved a hypothetical situation, participant
responses were not made in the context of making an
actual clinical decision. The study sample was a small
convenience sample of volunteers and the stability of
their preferences was not assessed. Consequently, the re-
sults of this study may not adequately reflect findings
from the general patient population. Finally, we made no
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dashboard into routine patient care. None of these limi-
tations, however, negates the primary finding of the
study, i.e., that the interactive dashboard format can be
successfully adapted to create a patient decision aid cap-
able of quickly and efficiently helping at least some
people identify preferred decision alternatives based on a
large amount of complex data.
It is important to note that this study was designed to
assess the feasibility of creating a patient decision aid
using the interactive dashboard format rather than to
evaluate the effectiveness of this approach or examine
treatment preferences for osteoarthritis pain. Conse-
quently, additional research is needed to determine ef-
fectiveness in a general patient population. Moreover,
additional studies are needed to determine the amount
and type of information clinical decision dashboards
should contain, how to effectively involve busy prac-
titioners in their use, and to explore the efficiency, ef-
fectiveness, and cost-effectiveness of using interactive
dashboards to support patient-centered shared decision
making in routine practice settings.
Conclusions
In conclusion, these results suggest that an interactive
clinical decision dashboard, either used alone or in con-
junction with more traditional print-based reference ma-
terials, has the potential to be an effective and efficient
format for creating clinical decision aids capable of fos-
tering informed patient decision making and patient-
centered care.
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